Is Ecolab Stock Worth Buying as Growth Rises but Debt Risk Builds?

Ecolab's Growth Engines Keep Expanding

Global High-Tech organic sales rose 29% in the second quarter of 2026, while Ecolab Digital sales increased 27%. Global Life Sciences organic sales advanced 15%, led by bioprocessing, pharmaceuticals and personal care.

These businesses broaden Ecolab’s growth mix beyond slower industrial operations. High-Tech is benefiting from semiconductor and data-center demand, while Digital and Life Sciences add software, connected solutions and regulated-production exposure to the company’s portfolio.

Image Source: Zacks Investment Research

ECL's Pricing and Productivity Support Margins

Second-quarter organic sales increased 5%, supported by 4% pricing and 1% volume growth. The volume gain came despite an approximately 1 percentage-point headwind from Middle East customer disruptions, while higher pricing helped offset rising commodity costs.

Organic operating income margin expanded 40 basis points to 18.8%. Management expects pricing to strengthen to 5%-6% in the second half and targets an organic operating income margin of about 20%, supported by productivity and cost savings.

Ecolab's Debt Load Complicates the Bull Case

Total debt reached $13.18 billion at the end of the second quarter, up from $8.49 billion at the end of the first quarter as Ecolab raised financing for recent acquisitions, including CoolIT Systems.

Net interest expense increased to $73.1 million from $63.2 million a year earlier. The higher financing burden, together with acquisition-related non-cash amortization, creates a near-term earnings offset even as CoolIT expands Ecolab’s data-center opportunity.

ECL Still Faces Macro and Competitive Pressure

Heavy Water organic sales declined 1% in the second quarter as softer basic-industry demand and weaker Middle East activity weighed on results. Energy volatility and geopolitical disruption could also pressure volumes or delay margin recovery if costs rise faster than pricing actions.

Competition adds another constraint. Pentair plc PNR operates across residential, commercial and industrial water solutions, overlapping with parts of Ecolab’s water-management exposure. The Clorox Company CLX also competes in health and hygiene markets, where its portfolio now includes Clorox Professional and Purell.

Price-sensitive customers may resist repeated increases, making value-based pricing harder to sustain if lower-cost alternatives gain traction. That risk matters because Ecolab’s margin outlook assumes pricing and productivity will continue to offset inflation.

Image Source: Zacks Investment Research

Ecolab's Earnings Outlook Offers Near-Term Support

Ecolab raised its 2026 adjusted earnings guidance to $8.05-$8.25 per share from $8.03-$8.23, implying growth of 7%-10%. Management also expects second-half organic sales growth of 6%-7%.

Accelerating pricing, productivity and share gains support that outlook. Still, the guidance includes short-term non-cash amortization and financing costs related to CoolIT, so stronger operating performance must absorb part of the acquisition burden.

ECL's Underperform Signal Keeps the Bar High

Ecolab’s faster growth and improving margins strengthen the operating case, but higher leverage leaves less room for execution setbacks. The company must sustain growth while integrating acquisitions, protecting margins and managing a heavier financing load.

ECL currently carries a Zacks Rank #4 (Sell). Its Momentum Score of A is favorable, but the Value Score of F, Growth Score of C and VGM Score of D present a more cautious overall Style Score profile.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks Style Scores are designed to complement the Zacks Rank rather than override it. The strong Momentum Score points to favorable price-trend characteristics, but the weaker Value and VGM readings, combined with the Zacks Rank #4, keep the near-term setup cautious.

For investors weighing whether to buy now or wait, the current signals favor patience rather than treating the company’s improving growth alone as sufficient reason to enter.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research